Benjamin L Palleiko, the CHIEF EXECUTIVE OFFICER of $KALV ($KALV), sold 7,627 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Paul K. Audhya, the CHIEF MEDICAL OFFICER of $KALV ($KALV), sold 2,187 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.2%...
Christopher Yea, the CHIEF DEVELOPMENT OFFICER of $KALV ($KALV), sold 1,963 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
/CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences...
Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (June) Construction ...
Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) Reported EPS of 90 cents ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...